Naltrexone is not approved for any anxiety disorder, and controlled trials targeting anxiety as a primary condition have mostly come up empty. That said, the relationship between naltrexone and anxiety is more tangled than a simple yes or no, because the drug touches the same brain chemistry that regulates stress and emotional pain. In certain situations, particularly when anxiety rides alongside alcohol dependence, dissociative symptoms, or severe emotional dysregulation, naltrexone appears to pull anxiety down as a secondary benefit. The question is really about context: whose anxiety, under what circumstances, and at what dose.
Why People Think an Opioid Blocker Might Help Anxiety
Naltrexone works by blocking opioid receptors, primarily the mu-opioid receptor and, to a lesser extent, kappa and delta receptors. At first glance, blocking the brain’s own feel-good system sounds like it would make anxiety worse, not better. But the endogenous opioid system does more than just produce pleasure. It regulates how the brain processes threats, modulates the stress hormone cascade, and shapes how we respond emotionally to painful social situations.
Research on the opioid system shows that its different receptor types have different roles in anxiety. Mice lacking delta-opioid receptors, for instance, show anxiety-like behavior, while blocking or knocking out kappa-opioid receptors tends to reduce stress responses.1PubMed Central. Stress-Induced Changes in the Endogenous Opioid System Cause Dysfunction of Pain and Emotion Regulation Kappa-opioid receptor antagonism in particular has attracted interest as a potential treatment for stress-related psychiatric conditions because disrupting kappa signaling appears to prevent the development of stress-driven changes in brain circuits.2PubMed Central. Role of kappa-opioid receptors in stress and anxiety-related behavior Naltrexone hits kappa receptors in addition to mu receptors, which is part of why researchers have explored it for anxiety-adjacent conditions.
Brain imaging in humans confirms the opioid system activates in response to acute threat. When people face fear-related cues, opioid receptor binding increases across regions involved in threat processing, including the thalamus, hippocampus, and cingulate cortex.3Molecular Psychiatry. Endogenous opioid system modulates proximal and distal threat signals in the human brain So there is a legitimate biological rationale for thinking that manipulating opioid signaling could shift how the brain handles anxiety. The question is whether that rationale translates into clinical results.
What Happens When You Test It Against Primary Anxiety
The short version: it mostly has not worked. A review of placebo-controlled studies looking at naltrexone for anxiety disorders found that the drug failed to demonstrate clear efficacy.4Journal of the American Academy of Child & Adolescent Psychiatry. Anxiolytics, Adrenergic Agents, and Naltrexone No major clinical guidelines recommend naltrexone as a standalone treatment for generalized anxiety, social anxiety, or panic disorder. The drug simply has not cleared the bar in the kinds of trials that would justify that use.
A similar pattern shows up in PTSD research. An open-label study of naltrexone in PTSD patients found only subtle improvements in intrusive and hyperarousal symptoms, and the researchers described the benefit as clinically insignificant. On top of that, patients were hypersensitive to side effects, which limited dosing. The study authors concluded that the results did not encourage the use of naltrexone for PTSD.5Human Psychopharmacology. Short-term treatment of post-traumatic stress disorder with naltrexone: An open-label preliminary study
This is where many discussions of naltrexone and anxiety stop. But stopping here misses the more interesting part of the story, because when researchers look at people who have anxiety alongside another condition naltrexone is already being used for, the picture changes.
Anxiety in People With Alcohol Use Disorder
Naltrexone is FDA-approved for alcohol use disorder, and many people who drink heavily also struggle with anxiety. That overlap creates a natural experiment: when naltrexone reduces drinking, does the anxiety come down too?
Evidence suggests it does. In a trial comparing naltrexone to disulfiram (another anti-alcohol medication), investigators found that anxiety symptoms improved in both treatment groups. Among patients who also had PTSD, those receiving active medication had significantly better outcomes for both abstinence and psychiatric symptoms.6Frontiers in Psychiatry. Treatment of Comorbid Alcohol Dependence and Anxiety Disorder: Review of the Scientific Evidence and Recommendations for Treatment A neuroimaging sub-study in people with alcohol use disorder found that both naltrexone and topiramate reduced anxiety scores substantially over six weeks of treatment, with participants scoring within the normal range for anxiety by the end.7Alcohol and Alcoholism. Comparative effects of topiramate and naltrexone on neural activity during anticipatory anxiety in individuals with alcohol use disorder
There is a chicken-and-egg question here. Is naltrexone directly reducing anxiety through its action on the opioid system? Or is it just reducing alcohol craving and consumption, which in turn lowers the anxiety that heavy drinking perpetuates? Some evidence points toward a more direct mechanism. Naltrexone has been shown to raise cortisol levels and lower alcohol craving at the same time, and cortisol levels were inversely related to craving intensity.8PubMed. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis That cortisol bump probably reflects the stress axis recalibrating after opioid blockade, which could shift anxiety processing independently of drinking behavior. But untangling the two effects cleanly is difficult, and no one has managed it yet.
Dissociation, Depersonalization, and Emotional Dysregulation
Some of the most intriguing signals for naltrexone and anxiety-related symptoms come from conditions where emotional processing goes haywire rather than from anxiety disorders per se.
Dissociative symptoms, including depersonalization and derealization, are often experienced as intensely distressing and frequently co-occur with anxiety. A systematic review and meta-analysis of opioid antagonists for dissociation found a large treatment effect, though the included studies were heterogeneous and publication bias may have been present.9PubMed Central. Treatment of dissociative symptoms with opioid antagonists: a systematic review A separate open trial in depersonalization disorder found an average 30% reduction in symptoms over six to ten weeks of naltrexone treatment, with several patients rated as much improved or very much improved. The researchers described these results as promising for a condition that has no established treatment guidelines.10PubMed. An open trial of naltrexone in the treatment of depersonalization disorder
In borderline personality disorder, where emotional dysregulation drives chronic anxiety, anger, and impulsive behavior, a retrospective analysis of inpatients found that naltrexone was the only medication associated with significant improvement. The effect was striking: patients treated with naltrexone recovered more often than those on other drugs, and higher doses were more effective than lower doses, though even low doses outperformed other pharmacological treatments.11PubMed. Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients This is a retrospective study, not a randomized trial, so the evidence is weaker than it looks at first glance. But for a condition where medication options are limited, the signal is hard to ignore.
What these conditions share is that the anxiety is not free-floating; it is woven into a broader pattern of abnormal opioid-mediated emotional processing. That may be why naltrexone helps there and not in straightforward generalized or social anxiety.
The Low-Dose Naltrexone Question
Low-dose naltrexone (LDN), typically taken at around 1 to 5 mg rather than the standard 50 mg, has developed a large following online for conditions ranging from chronic pain to autoimmune disease. Anxiety is among the symptoms people report improvement in, and there is a theoretical framework for why it might work differently at low doses. But the human evidence for LDN and anxiety specifically is thin.
The core idea behind LDN is the “rebound effect.” A brief, partial blockade of opioid receptors prompts the body to compensate by producing more endogenous opioids and upregulating opioid receptors.12PubMed Central. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain This upregulation has been demonstrated in both animal and laboratory models.13PubMed. Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes In diabetic mice after stroke, acute LDN treatment increased levels of beta-endorphin, a key endogenous opioid, and promoted neuronal recovery.14PubMed. Acute Low Dose Naltrexone Increases β-Endorphin and Promotes Neuronal Recovery Following Hypoxia-Ischemic Stroke in Type-2 Diabetic Mice The idea is that you end up with more natural opioid signaling after the drug wears off than you had before, which could calm anxiety through better endogenous regulation.
In an animal model relevant to this discussion, mice that had been chronically exposed to alcohol and showed anxiety-like behavior had those deficits reversed after two weeks of naltrexone treatment. The mice spent more time in open, exposed areas of a test maze, which is the standard measure of reduced anxiety in rodents.15PubMed Central. Naltrexone treatment improves anxiety- and depression-like behavior in alcohol-exposed mice That is encouraging, but mouse behavior on a maze does not always predict what happens in human clinical anxiety. And at ultra-low doses (below 1 mg), the pharmacology shifts further: naltrexone begins modulating neuroinflammation and interacting with opioid signaling in ways that are distinct from its receptor-blocking action at standard doses.16PubMed. Antinociceptive effect of ultra-low dose naltrexone in a pre-clinical model of postoperative orofacial pain
The honest assessment is that LDN’s effects on anxiety in humans remain largely anecdotal. A nationwide register-based study in Norway acknowledged that LDN’s psychiatric applications are mostly unexplored territory, with its main established use in psychiatry still being addiction treatment.17Scientific Reports. Changes in the consumption of antiepileptics and psychotropic medicines after starting low dose naltrexone: A nation-wide register-based controlled before-after study The rebound hypothesis is plausible and has some preclinical support, but no one has run a proper randomized controlled trial of LDN for anxiety disorders in humans.
When Naltrexone Can Make Anxiety Worse
This is a real concern, and it comes from several directions. First, there is the issue of dysphoria. Naltrexone has a reputation for making some people feel emotionally flat or low. A double-blind placebo-controlled trial found that in healthy, non-addicted people, naltrexone did not significantly alter mood over two months. But the researchers noted that subpopulations under physiological or psychological stress may react with dysphoric symptoms, and one participant had to be pulled from the study for a severe dysphoric reaction.18Biological Psychiatry. Naltrexone and dysphoria: A double-blind placebo controlled trial If you already have anxiety, you are by definition under psychological stress, which may make you more vulnerable to this side effect.
Second, the naltrexone/bupropion combination marketed for weight loss (Contrave) has been associated with higher rates of anxiety. A pooled analysis of trial data found that about 5% of people on the combination reported anxiety compared to about 3% on placebo. Sleep disturbances were even more common, affecting roughly 13% versus 8% on placebo.19PubMed Central. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis The bupropion component likely plays a role here, but if you are taking this combination and your anxiety is worsening, it is worth knowing that the naltrexone piece is not necessarily the protective factor you might hope for.
Third, and more subtly, naltrexone interacts with how the brain responds to other anxiety treatments. An animal study found that injecting naltrexone into the central amygdala, a brain region critical for fear processing, blocked the anxiety-reducing effects of diazepam (Valium). The drug did not increase anxiety on its own in that study, but it prevented a standard anxiolytic from working.20PubMed Central. Microinjection of naltrexone into the central, but not the basolateral, amygdala blocks the anxiolytic effects of diazepam in the plus maze That is an animal finding and involved direct brain injection rather than oral dosing, so it does not map neatly onto clinical practice. But it hints that opioid blockade may interfere with some of the brain’s built-in calming mechanisms, which could matter if you are also taking benzodiazepines.
The Social Warmth Trade-Off
One of the more underappreciated effects of naltrexone is what it does to social connection, which is deeply relevant for anyone whose anxiety involves interpersonal situations or loneliness. The endogenous opioid system is heavily involved in how the brain processes social warmth, belonging, and bonding. Blocking it changes that processing.
In a study where participants read affectionate messages from close friends, family members, and romantic partners, naltrexone reduced brain activity in reward regions compared to placebo. In the placebo group, people who reported feeling more socially connected showed stronger brain responses to these warm messages. In the naltrexone group, that link between feeling connected and neural response was erased entirely.21PubMed Central. Naltrexone alters responses to social and physical warmth: implications for social bonding
A systematic review and meta-analysis confirmed this pattern more broadly: naltrexone has a statistically significant negative effect on social connectedness, with a small but real effect size. The reductions in social connection tended to come with decreases in positive mood and increases in negative mood.22Translational Psychiatry. Endogenous mu-opioid modulation of social connection in humans: a systematic review and meta-analysis For someone with social anxiety, this is a complicated finding. On one hand, dulling the emotional intensity of social interactions might reduce the sting of perceived rejection. On the other hand, if the drug blunts your ability to feel warmth from positive social experiences, you lose one of the most effective natural antidotes to anxiety. The net effect is unclear and probably varies person to person.
Why Genetics Might Determine Whether It Helps You
One reason the research is so mixed may be that naltrexone’s effects depend heavily on individual biology. A well-studied genetic variation in the mu-opioid receptor gene, known as the A118G polymorphism, has been linked to differences in pain sensitivity, stress response, alcohol-related behavior, and crucially, treatment response to naltrexone.23Alcohol and Alcoholism. The µ-Opioid Receptor and Treatment Response to Naltrexone People with one version of this gene seem to get more benefit from naltrexone in alcohol treatment than people with another version.
Whether this genetic variation also predicts who might experience anxiety relief from naltrexone has not been directly tested in anxiety trials. But the logic is straightforward: if your opioid system is wired differently at the receptor level, the same dose of an opioid blocker will produce different downstream effects on stress hormones, social processing, and emotional regulation. Naltrexone’s effects on the stress hormone axis, for instance, vary between people. In one study, naltrexone triggered cortisol and ACTH responses in healthy controls, but in people recovering from alcohol dependence, the cortisol response was blunted.24PubMed. Hypothalamic-pituitary-adrenal axis response to oral naltrexone in alcoholics during early withdrawal That kind of variability helps explain why the same drug can reduce anxiety in one person and feel awful in another.
Off-Label Prescribing and Where the Field Stands
Naltrexone is already prescribed off-label for a range of conditions well beyond its formal approvals for alcohol and opioid use disorders. Case reports document anxiety improvement alongside primary targets like compulsive behaviors.25PubMed Central. Off-Label Use of Naltrexone in Pica and Other Compulsive Behaviors: A Report of Two Cases In pediatric populations with autism spectrum disorder, naltrexone has been used primarily to reduce self-injurious behavior, but improvements in related symptoms including social withdrawal and agitation have also been noted.26PubMed Central. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder These are not anxiety trials, but they illustrate how naltrexone can shift emotional and behavioral regulation in ways that touch anxiety indirectly.
The pattern across all of this research is consistent: naltrexone’s anxiety effects are almost always secondary findings in studies designed to look at something else. Nobody has run a large, well-powered, randomized trial specifically asking whether naltrexone reduces anxiety in people diagnosed with generalized anxiety disorder, social anxiety disorder, or panic disorder. Until someone does, the honest answer remains that naltrexone has not proven itself for primary anxiety, but keeps showing up as a helpful player when anxiety is entangled with other conditions the drug already treats. If you are considering naltrexone specifically because of anxiety, the context of that anxiety matters enormously. Anxiety driven by alcohol dependence, emotional dysregulation, or dissociative processes has the most evidence behind it. Anxiety with no clear co-occurring condition has essentially none.